TY - JOUR
T1 - Rituximab for treatment-resistant extensive Wegener's granulomatosis- additive effects of a maintenance treatment with leflunomide
AU - Henes, J. C.
AU - Fritz, J.
AU - Koch, S.
AU - Klein, R.
AU - Horger, M.
AU - Risler, T.
AU - Kanz, L.
AU - Koetter, I.
PY - 2007/10
Y1 - 2007/10
N2 - Extensive Wegener's granulomatosis (WG) is treated by glucocorticosteroids (GC) and cyclophosphamide (CYC). In some cases, the disease is refractory to CYC. For those patients the depletion of B-lymphocytes with rituximab is a promising new treatment modality. This is a retrospective study of six patients receiving rituximab (RTX) with 4 × 375 mg/m2 body surface weekly because of inefficacy of CYC. Proteinase-3-antineutrophil cytoplasmic antibodies (PR3-ANCA) and c-ANCAs were assessed. For clinical follow-up the Birmingham Vasculitis Activity Score for WG (BVAS/WG) was used. In five of the six cases, leflunomide (LEF) was given as maintenance treatment. Mean follow up was 16 months (12-21 months). The median PR3-ANCA titer fell from 36.8 U/ml at baseline to 21.4 U/ml after 3 months, 8.3 after 6 months, and 4.3 at month 12. The median BVAS/WG at baseline was 5 and 0 after 1 month. Two minor relapses could be noticed at month 3. After 6 months, one patient still had a BVAS of 1, all the others had a BVAS of 0. At month 18, a major relapse occurred in one patient, which was successfully retreated with RTX. The RTX infusions were well tolerated. Rituximab is a well-tolerated, very effective medication for patients with Wegener's granulomatosis. Leflunomide maintenance may increase the efficacy of rituximab and prolong the disease-free period.
AB - Extensive Wegener's granulomatosis (WG) is treated by glucocorticosteroids (GC) and cyclophosphamide (CYC). In some cases, the disease is refractory to CYC. For those patients the depletion of B-lymphocytes with rituximab is a promising new treatment modality. This is a retrospective study of six patients receiving rituximab (RTX) with 4 × 375 mg/m2 body surface weekly because of inefficacy of CYC. Proteinase-3-antineutrophil cytoplasmic antibodies (PR3-ANCA) and c-ANCAs were assessed. For clinical follow-up the Birmingham Vasculitis Activity Score for WG (BVAS/WG) was used. In five of the six cases, leflunomide (LEF) was given as maintenance treatment. Mean follow up was 16 months (12-21 months). The median PR3-ANCA titer fell from 36.8 U/ml at baseline to 21.4 U/ml after 3 months, 8.3 after 6 months, and 4.3 at month 12. The median BVAS/WG at baseline was 5 and 0 after 1 month. Two minor relapses could be noticed at month 3. After 6 months, one patient still had a BVAS of 1, all the others had a BVAS of 0. At month 18, a major relapse occurred in one patient, which was successfully retreated with RTX. The RTX infusions were well tolerated. Rituximab is a well-tolerated, very effective medication for patients with Wegener's granulomatosis. Leflunomide maintenance may increase the efficacy of rituximab and prolong the disease-free period.
KW - Leflunomide
KW - Maintenance therapy
KW - Rituximab
KW - Wegener's granulomatosis
UR - http://www.scopus.com/inward/record.url?scp=34548628288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548628288&partnerID=8YFLogxK
U2 - 10.1007/s10067-007-0643-9
DO - 10.1007/s10067-007-0643-9
M3 - Article
C2 - 17502992
AN - SCOPUS:34548628288
SN - 0770-3198
VL - 26
SP - 1711
EP - 1715
JO - Clinical rheumatology
JF - Clinical rheumatology
IS - 10
ER -